Tenax Therapeutics Presents Phase 3 Data at ESC Congress 2026

On the afternoon of 29 August 2026, Tenax Therapeutics, Inc. (NASDAQ: TENX) announced that it will present the results of its pivotal Phase 3 LEVEL study during the late‑breaking scientific sessions of the European Society of Cardiology (ESC) Congress 2026. The presentation follows the company’s recent release of additional Phase 3 data for its investigational product, TNX‑103, as reported by multiple financial news outlets on the same day.

Key Details of the LEVEL Study

The LEVEL study is a multicentre, double‑blind, placebo‑controlled trial evaluating the efficacy and safety of levosimendan‑based therapy in patients with pulmonary hypertension associated with heart failure and preserved ejection fraction (PH‑HFPf). Tenax Therapeutics has positioned levosimendan—a calcium sensitizer originally approved for acute heart failure—as the active ingredient in its development program, aiming to address a significant unmet medical need in critical care.

  • Trial Design: Approximately 1,200 participants across 20 sites in Europe, North America, and Asia are randomized 1:1 to receive either TNX‑103 or placebo for 12 months.
  • Primary Endpoint: Change from baseline in the 6‑minute walk distance (6MWD) at 12 months, a clinically meaningful measure of exercise capacity in PH patients.
  • Secondary Endpoints: Include time to first clinical event, pulmonary vascular resistance, and quality‑of‑life assessments using the Kansas City Cardiomyopathy Questionnaire (KCCQ).

The company’s leadership highlighted that the Level study is designed to meet regulatory requirements for the eventual approval of TNX‑103 as a therapeutic option for PH‑HFPf, a population with limited treatment options.

Additional Phase 3 Data for TNX‑103

In parallel with the ESC Congress announcement, Tenax disclosed supplementary data from the same Phase 3 program. The additional results, shared with investors and analysts via an investor‑relations briefing, showed a statistically significant improvement in the primary endpoint with a mean increase of 55 meters in 6MWD versus placebo (p < 0.001). Furthermore, the safety profile remained consistent with the known adverse events of levosimendan, with no new safety signals identified.

  • Safety Overview: The incidence of serious adverse events was comparable between the TNX‑103 and placebo groups, reinforcing the drug’s tolerability in the chronic PH‑HFPf setting.
  • Exploratory Biomarkers: Early data suggest a favorable impact on biomarkers of myocardial stress, such as NT‑proBNP, although these findings await formal statistical analysis.

Market Context and Company Position

Tenax Therapeutics, headquartered in Morrisville, United States, has maintained a modest market cap of approximately $81.9 million, reflecting its early‑stage status and narrow therapeutic focus. The company’s stock, trading at $2.13 on 27 August 2026, has seen volatility with a 52‑week high of $19.40 and a low of $1.31, indicative of the speculative nature of biotech investments.

Despite the current price‑earnings ratio of –1.44, the firm’s clinical pipeline and the strategic focus on levosimendan—a compound with a well‑established safety profile—provide a compelling narrative for potential long‑term value. The upcoming presentation at ESC 2026 is expected to be a critical juncture for the company, potentially influencing future regulatory filings and investor sentiment.

Outlook

If the LEVEL study outcomes are positive and meet the criteria set by regulatory authorities, Tenax Therapeutics could be positioned to file an application for market authorization in key regions, including the European Union and the United States. The company’s commitment to addressing a high‑unmet medical need in pulmonary hypertension, combined with its active ingredient’s clinical history, may attract additional strategic partnerships or investment.

Investors and clinicians alike will closely monitor the ESC Congress presentation for detailed efficacy and safety data, as well as for insights into the company’s next steps in bringing TNX‑103 to patients worldwide.